Resistant Bacterial Infections in the Early Post LDLT Period

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this work was to study the incidence, types, risk factors and causative organisms of bacterial infections in HCV Egyptian patients following Liver Transplantation. Moreover, to identify the emerging resistant strains and their proper antimicrobial therapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Outcomes of Living Donor Liver Transplantations With Anti-HBc (+) Grafts in Pediatric Patients

NCT06290726

Living Donor Liver Transplantations With Anti-HBc (+) Grafts

COMPLETED

Risk of Post Transfusion Hepatitis C Virus Infection

NCT00005339

Hepatitis, Viral, Human Blood Transfusion Blood Donors

COMPLETED

Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection

NCT01090232

Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection

COMPLETED NA

Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta

NCT04170452

Chronic Hepatitis Delta Liver Biopsy

UNKNOWN

Hepatitis B Virus Infection After Liver Transplantation in Children

NCT03865966

Hepatitis B Infection

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective descriptive study has been done at Tropical Medicine department in the period between January 2014 to November 2015.

After the approval of the scientific and ethical committee of Ain Shams University Hospital, Patients with HCV positive end stage liver disease (ESLD) eligible for liver transplantation Ain Shams Center for Organ Transplant (ASCOT); Ain Shams University, (fulfilling the inclusion criteria) were included in the current study. Forty five patients were recruited and each one was followed-up during a period of 3 months following transplantation.

Included patients were divided into 2 groups:

Group 1 included patients who had a postoperative single episode of infection. Group 2 included those patients who had more than 1 episode of postoperative bacterial infection whom were further evaluated for the presence of emerging strains and/or antibiotic resistance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transplantation Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HCV patients following living donor liver transplantation

single infection episode group

Living donor liver transplantation

Intervention Type PROCEDURE

patients following living donor liver transplantation

recurrent Infections episode group

Living donor liver transplantation

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Living donor liver transplantation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Egyptian nationality.
* Accepting participation in the current study and signing a written consent form
* Age between 18-60 Years, including males and females.

Exclusion Criteria

* Patients who refused to be enrolled in the study.
* Patients with other etiologies for end-stage liver disease (HBV, PBC…)
* Patients with preoperative infections, infections within 48 h after transplantation or early post-operative death

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No